{"meshTags":["Antibodies, Monoclonal","Antibodies, Monoclonal, Humanized","Antineoplastic Combined Chemotherapy Protocols","Bevacizumab","Camptothecin","Capecitabine","Cetuximab","Chemotherapy, Adjuvant","Colonic Neoplasms","Community Health Nursing","Deoxycytidine","Drug Monitoring","Fluorouracil","Home Infusion Therapy","Humans","Nurse\u0027s Role","Organoplatinum Compounds","Survival Rate","Treatment Outcome"],"meshMinor":["Antibodies, Monoclonal","Antibodies, Monoclonal, Humanized","Antineoplastic Combined Chemotherapy Protocols","Bevacizumab","Camptothecin","Capecitabine","Cetuximab","Chemotherapy, Adjuvant","Colonic Neoplasms","Community Health Nursing","Deoxycytidine","Drug Monitoring","Fluorouracil","Home Infusion Therapy","Humans","Nurse\u0027s Role","Organoplatinum Compounds","Survival Rate","Treatment Outcome"],"genes":["oxaliplatin"],"organisms":["9606"],"publicationTypes":["Journal Article","Review"],"abstract":"Adjuvant chemotherapy for colon cancer has changed significantly during the past 5 years. The traditional agent fluorouracil has been joined by new drugs, including capecitabine, irinotecan, oxaliplatin, and targeted agents such as bevacizumab and cetuximab. These new agents bring different mechanisms of action, different side effects, and new home care nursing implications. Significant improvements in disease-free remissions and survival rates are among the many benefits of these therapies to persons with colon cancer. This article covers these newer agents, targeted therapies for colon cancer, and associated nursing and patient implications, including detailed drug information.","title":"Advances in colon cancer chemotheapy: nursing implications.","pubmedId":"15764920"}